Urothelial Carcinoma

• FDA label_change · 2023-12-15
  FDA Approved: PADCEV EJFV — Supplemental Application (SEAGEN INC.)

  FDA supplemental application submitted for PADCEV EJFV (enfortumab vedotin) by Seagen.

• FDA label_change · 2023-04-18
  FDA Approved: PADCEV EJFV — Supplemental Application (SEAGEN INC.)

  FDA notes a supplemental application for PADCEV EJFV (enfortumab vedotin) from Seagen, likely seeking labeling changes or expansion of the a…